when the disease progresses to relapsed multiple myeloma or refractory multiple myeloma is that the disease itself becomes more complicated and is continuously developing resistance to treatments.8
For relapsed refractory multiple myeloma specifically, studies have found that CD38, a receptor on multiple myeloma cells and cell surface receptors, is a prime target for anti-body based therapeutics.
By targeting CD38 receptors, monoclonal antibodies, such as Sanofi’s Sarclisa (isatuximab-irfc), are able to bind to the CD38 receptors on multiple myeloma cells to help the body identify and remove the harmful myeloma cells.9
Sarclisa is an FDA-approved treatment option, in combination with two other treatments named pomalidomide and dexamethasone – commonly known as pom-dex – in the clinical setting.9
As Dr. Buck states, “Specifically, Sarclisa is approved for the treatment of adults with relapsed refractory multiple myeloma.”9
Since relapsed refractory multiple myeloma refers to a specific type of multiple myeloma, patients who are eligible for Sarclisa must have received at least two prior therapies, including lenalidomide and a type of treatment called a proteasome inhibitor.9
Robert Pugh, who has been living with multiple myeloma since 2014 and regularly interacts with other individuals living with this debilitating disease, has some advice for patients diagnosed with multiple myeloma, “It’s important to be transparent with your doctor and discuss the best approaches for you as a multiple myeloma patient or as a caregiver.
There’s nothing wrong with